Bariatric surgery and the perioperative management of type 2 diabetes: Practical guidelines
Publication date: Available online 7 August 2019Source: Journal of Visceral SurgeryAuthor(s): F. Galtier, F. Pattou, S. Czernichow, E. Disse, P. Ritz, J.-M. Chevallier, E. Cosson, P. Valensi, F. Andreelli, M. Robert, DIAMS study groupSummaryBackgroundMetabolic surgery is now considered as a therapeutic option in type 2 diabetes (T2D). However, few data are available regarding perioperative management of T2D.ObjectivesTo assess current practice among bariatric teams regarding perioperative management of T2D in order to propose guidelines.MethodsA two-round Delphi method using online surveys was employed among bariatric teams experts (surgeons, diabetologists, anesthetists, nutritionists): first round, 63 questions covering 6 topics (characteristics of experts/teams, characteristics of patients, operative technique, pre/postoperative management, diabetes remission); second round, 44 items needing clarification. They were discussed within national congress of corresponding learned societies. Consensus was defined as ≥ 66% agreement.ResultsA total of 170 experts participated. Experts favored gastric bypass to achieve remission (76.7%). Screening for retinopathy, cardiac ultrasound, and reaching an HbA1c
HbA1c values also declined across a sample of program participants, many of whom said they were unfamiliar with the diabetes management tools prior to enrollment.
CONCLUSION: All these results indicate that SQC is an effective preventive and protective drug on skeletal muscle of diabetic macrovasculopathy, and could alleviate skeletal muscle tissue damage through affecting biological functions related to cell death and cell adhesion. PMID: 32096754 [PubMed - as supplied by publisher]
Condition: Diabetes Mellitus, Type 2 Intervention: Device: iRF System Hepatic Denervation Sponsor: Metavention Not yet recruiting
Condition: Diabetes Mellitus, Type 2 Interventions: Dietary Supplement: Vitamin K; Other: Placebo Sponsor: Cairo University Recruiting
Condition: Type 2 Diabetes Mellitus Intervention: Drug: Trelagliptin Sponsor: Takeda Not yet recruiting
Changes in labeling, formularies, and drug formulations were among the factors contributing to shifts in type 2 diabetes drug prescribing practices in the US.Medscape Medical News
Abstract The sum of squared score (SSU) and sequence kernel association test (SKAT) are the two good alternative tests for genetic association studies in case-control data. Both SSU and SKAT are derived through assuming a dose-response model between the risk of disease and genotypes. However, in practice, the real genetic mode of inheritance is impossible to know. Thus, these two tests might losepower substantially as shown in simulation results when the genetic model is misspecified. Here, to make both the tests suitable in broad situations, we propose two-phase SSU (tpSSU) and two-phase SKAT (tpSKAT), where the ...
CONCLUSIONS: The mechanism underlying this phenomenon relates to a decrease in the inflammatory reaction and oxidative stress, as well as a decrease in leaky gut. Such reactions increase insulin sensitivity and reduce autoimmune responses. PMID: 32096204 [PubMed - in process]